Detalhe da pesquisa
1.
Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi-Bickel syndrome with empagliflozin.
J Inherit Metab Dis
; 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38802119
2.
Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value-based healthcare approach and systematic benefit-risk assessment.
J Inherit Metab Dis
; 47(2): 244-254, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185897
3.
Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
Antimicrob Agents Chemother
; 66(7): e0000322, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35727060
4.
Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients.
Antimicrob Agents Chemother
; 66(2): e0182921, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807758
5.
Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
Clin Infect Dis
; 67(suppl_3): S327-S335, 2018 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30496467
6.
Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
Clin Infect Dis
; 67(suppl_3): S303-S307, 2018 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30496466
7.
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
N Engl J Med
; 382(24): 2376-2377, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32521142
8.
Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.
Ther Drug Monit
; 40(1): 17-37, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29120971
9.
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care.
Eur Respir J
; 60(6)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356974
10.
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
Eur Respir J
; 56(4)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32398308
11.
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
Eur Respir J
; 55(5)2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31980497
12.
Tuberculosis-Related Malnutrition: Public Health Implications.
J Infect Dis
; 220(2): 340-341, 2019 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30835281
13.
Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300â mg linezolid dosages using in-house made capsules.
Eur Respir J
; 54(6)2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439686
14.
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.
Eur Respir J
; 54(3)2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31048350
15.
Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.
Ther Drug Monit
; 41(2): 253-254, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30883521
16.
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
Eur Respir J
; 41(6): 1386-92, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22997218
17.
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.
Eur Respir J
; 42(6): 1614-21, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23520311
18.
Lack of penetration of amikacin into saliva of tuberculosis patients.
Eur Respir J
; 51(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326320
19.
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
Eur Respir J
; 51(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419442
20.
Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment.
Pharmaceuticals (Basel)
; 16(11)2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38004440